Smith & Nephew plc logo

Smith & Nephew plc

SNN

NYSEHealthcareMedical - Devices

Previous close

$29.26

+$0.22 · +0.76%

Aug 21, 4:00 PM ET

SNN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

88

Deep Value

Momentum

45

Neutral

Sentiment

58

Mixed

Risk resilience

68

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
GB
CEO
Deepak S Nath
Listed since
Nov 16, 1999
Employees
18,362

Market position

Day range

Current $29.26

52-week range

Current $29.26

Open
$28.775
Previous close
$29.04
Volume
790.54K
0.56× average
Average volume
1.42M
Average daily volume
Market cap
12.29B USD
Beta
0.69
Market reference 1
50-day average
$30.3346
-3.54% below average
200-day average
$32.2527
-9.28% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
16.99B USD
P/E (TTM)
19.2×
P/B (TTM)
2.38×
P/S (TTM)
1.92×
EV / EBITDA
12.72×
Earnings yield
4.40%
Free cash flow yield
5.99%
Dividend yield
2.72%

Profitability & efficiency

Gross margin
68.18%
Operating margin
16.69%
Net margin
10.08%
Return on equity
11.82%
Return on assets
5.98%
Return on invested capital
7.07%

Financial health

Debt / equity
0.73×
Current ratio
2.57×
Altman Z-score
3.88
Piotroski F-score
8 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends78%51%24%-2%Gross margin, FY2021: 70.95%Gross margin, FY2022: 70.95%Gross margin, FY2023: 70.19%Gross margin, FY2024: 70.21%Gross margin, FY2025: 68.25%Operating margin, FY2021: 11.38%Operating margin, FY2022: 8.63%Operating margin, FY2023: 7.66%Operating margin, FY2024: 11.31%Operating margin, FY2025: 12.88%Net margin, FY2021: 10.05%Net margin, FY2022: 4.28%Net margin, FY2023: 4.74%Net margin, FY2024: 7.09%Net margin, FY2025: 10.14%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 70.95%. Gross margin FY2022 70.95%. Gross margin FY2023 70.19%. Gross margin FY2024 70.21%. Gross margin FY2025 68.25%. Operating margin FY2021 11.38%. Operating margin FY2022 8.63%. Operating margin FY2023 7.66%. Operating margin FY2024 11.31%. Operating margin FY2025 12.88%. Net margin FY2021 10.05%. Net margin FY2022 4.28%. Net margin FY2023 4.74%. Net margin FY2024 7.09%. Net margin FY2025 10.14%.

Income trends

Revenue

6.16B USD+6.09%

Operating income

794M USD+20.85%

Net income

625M USD+51.70%
Income trends across reported periods6.76B USD4.38B USD2.01B USD−371.1M USDRevenue, FY2021: 5.21B USDRevenue, FY2022: 5.22B USDRevenue, FY2023: 5.55B USDRevenue, FY2024: 5.81B USDRevenue, FY2025: 6.16B USDOperating income, FY2021: 593M USDOperating income, FY2022: 450M USDOperating income, FY2023: 425M USDOperating income, FY2024: 657M USDOperating income, FY2025: 794M USDNet income, FY2021: 524M USDNet income, FY2022: 223M USDNet income, FY2023: 263M USDNet income, FY2024: 412M USDNet income, FY2025: 625M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 5.21B USD. Revenue FY2022 5.22B USD. Revenue FY2023 5.55B USD. Revenue FY2024 5.81B USD. Revenue FY2025 6.16B USD. Operating income FY2021 593M USD. Operating income FY2022 450M USD. Operating income FY2023 425M USD. Operating income FY2024 657M USD. Operating income FY2025 794M USD. Net income FY2021 524M USD. Net income FY2022 223M USD. Net income FY2023 263M USD. Net income FY2024 412M USD. Net income FY2025 625M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue6.16B USD5.81B USD5.55B USD5.22B USD5.21B USD
Cost of goods sold1.96B USD1.73B USD1.65B USD1.52B USD1.51B USD
Gross profit4.21B USD4.08B USD3.9B USD3.7B USD3.7B USD
Research and development346M USD343M USD339M USD345M USD356M USD
Selling, general, and administrative3.04B USD2.9B USD2.83B USD2.71B USD2.64B USD
Operating expenses3.41B USD3.42B USD3.47B USD3.25B USD3.11B USD
Interest income28.07M USD24.01M USD34.13M USD13.99M USD6M USD
Interest expense141.33M USD150.06M USD132.51M USD79.95M USD79.99M USD
Depreciation and amortization459M USD449M USD473M USD492M USD507M USD
Operating income794M USD657M USD425M USD450M USD593M USD
Net income625M USD412M USD263M USD223M USD524M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
-2.11%
11 comparable reports
Latest EPS result
0.95
Estimate 0.94 · Beat by 0.75%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.270.990.720.44Q3 '23MissQ3 '24MissQ4 '24MissQ1 '25BeatQ3 '25BeatQ1 '26BeatQ3 '26BeatQ1 '27Estimate
Q3 2023, reported Aug 3, 2023: actual 0.698, estimate 0.732, surprise -4.64%, Miss. Q3 2024, reported Aug 1, 2024: actual 0.752, estimate 0.786, surprise -4.33%, Miss. Q4 2024, reported Oct 31, 2024: actual 0.5, estimate 0.8, surprise -37.50%, Miss. Q1 2025, reported Feb 25, 2025: actual 0.938, estimate 0.92, surprise +1.96%, Beat. Q3 2025, reported Aug 5, 2025: actual 0.858, estimate 0.79, surprise +8.61%, Beat. Q1 2026, reported Mar 2, 2026: actual 1.18, estimate 1.16, surprise +1.72%, Beat. Q3 2026, reported Aug 4, 2026: actual 0.946, estimate 0.939, surprise +0.75%, Beat. Q1 2027, reported Feb 23, 2027: actual —, estimate 1.21, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates3.52B2.76B2.01B1.26BQ3 '23BeatQ3 '24BeatQ4 '24BeatQ1 '25BeatQ3 '25BeatQ1 '26BeatQ3 '26BeatQ1 '27Estimate
Q3 2023, reported Aug 3, 2023: actual 2.73B USD, estimate 2.72B USD, surprise +0.50%, Beat. Q3 2024, reported Aug 1, 2024: actual 2.83B USD, estimate 2.83B USD, surprise +0.07%, Beat. Q4 2024, reported Oct 31, 2024: actual 2.83B USD, estimate 1.41B USD, surprise +100.21%, Beat. Q1 2025, reported Feb 25, 2025: actual 2.98B USD, estimate 2.96B USD, surprise +0.70%, Beat. Q3 2025, reported Aug 5, 2025: actual 2.96B USD, estimate 1.53B USD, surprise +93.53%, Beat. Q1 2026, reported Mar 2, 2026: actual 3.2B USD, estimate 2.77B USD, surprise +15.48%, Beat. Q3 2026, reported Aug 4, 2026: actual 3.1B USD, estimate 1.64B USD, surprise +88.90%, Beat. Q1 2027, reported Feb 23, 2027: actual —, estimate 3.36B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$30.93

5.71% upside
Past 12 months12-month forecastHigh $31.85Average $30.93Low $30.00

Rating distribution

23 ratings
Strong buy00%
Buy626%
Hold1565%
Sell29%
Strong sell00%

Recent analyst actions

5 institutions
JP MorgandowngradeOverweightNeutral
BarclaysdowngradeEqual WeightUnderweight

SNN news

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$0.762

2025 complete year+1.6% since 2021

Corporate action history

DividendUpcoming

Ex-dividend Oct 2, 2026

$0.312

Semi-Annual

Record Oct 2, 2026 · Payment Nov 6, 2026

Dividend

Ex-dividend Oct 3, 2025

$0.30

Semi-Annual

Record Oct 3, 2025 · Payment Nov 7, 2025

Dividend

Ex-dividend Mar 28, 2025

$0.462

Semi-Annual

Record Mar 28, 2025 · Payment May 28, 2025

Dividend

Ex-dividend Oct 4, 2024

$0.288

Semi-Annual

Record Oct 4, 2024 · Payment Nov 8, 2024

Dividend

Ex-dividend Apr 1, 2024

$0.462

Semi-Annual

Record Apr 2, 2024 · Payment May 22, 2024

Dividend

Ex-dividend Oct 5, 2023

$0.288

Semi-Annual

Record Oct 6, 2023 · Payment Nov 1, 2023

SNN peers

ETFs holding SNN

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research SNN

research.disclaimer